Nabriva Therapeutics Ag Stock Cash Per Share
| NBRVDelisted Stock | USD 1.62 0.01 0.61% |
Nabriva Therapeutics AG fundamentals help investors to digest information that contributes to Nabriva Therapeutics' financial success or failures. It also enables traders to predict the movement of Nabriva Stock. The fundamental analysis module provides a way to measure Nabriva Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nabriva Therapeutics stock.
Nabriva |
Nabriva Therapeutics AG Company Cash Per Share Analysis
Nabriva Therapeutics' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Nabriva Therapeutics Cash Per Share | 7.53 X |
Most of Nabriva Therapeutics' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nabriva Therapeutics AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Nabriva Therapeutics AG has a Cash Per Share of 7.53 times. This is 73.1% higher than that of the Pharmaceuticals sector and 73.9% higher than that of the Health Care industry. The cash per share for all United States stocks is 50.3% lower than that of the firm.
Nabriva Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nabriva Therapeutics' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Nabriva Therapeutics could also be used in its relative valuation, which is a method of valuing Nabriva Therapeutics by comparing valuation metrics of similar companies.Nabriva Therapeutics is currently under evaluation in cash per share category among its peers.
Nabriva Fundamentals
| Return On Equity | -2.69 | |||
| Return On Asset | -0.65 | |||
| Profit Margin | (1.48) % | |||
| Operating Margin | (1.29) % | |||
| Current Valuation | 3.29 M | |||
| Shares Outstanding | 3.2 M | |||
| Shares Owned By Insiders | 0.96 % | |||
| Shares Owned By Institutions | 8.77 % | |||
| Number Of Shares Shorted | 44.59 K | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 0.24 X | |||
| Price To Sales | 0.17 X | |||
| Revenue | 35.67 M | |||
| Gross Profit | (10.23 M) | |||
| EBITDA | (54.7 M) | |||
| Net Income | (57.19 M) | |||
| Cash And Equivalents | 20.04 M | |||
| Cash Per Share | 7.53 X | |||
| Total Debt | 5.22 M | |||
| Debt To Equity | 0.21 % | |||
| Current Ratio | 2.81 X | |||
| Book Value Per Share | (1.36) X | |||
| Cash Flow From Operations | (36.71 M) | |||
| Short Ratio | 8.58 X | |||
| Earnings Per Share | (19.67) X | |||
| Price To Earnings To Growth | (0.06) X | |||
| Target Price | 1.0 | |||
| Number Of Employees | 39 | |||
| Beta | 1.56 | |||
| Market Capitalization | 4.55 M | |||
| Total Asset | 31.77 M | |||
| Retained Earnings | (652.86 M) | |||
| Working Capital | 3.5 M | |||
| Current Asset | 83 M | |||
| Current Liabilities | 14 M | |||
| Z Score | -32.68 | |||
| Net Asset | 31.77 M |
About Nabriva Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nabriva Therapeutics AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nabriva Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nabriva Therapeutics AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Other Consideration for investing in Nabriva Stock
If you are still planning to invest in Nabriva Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Nabriva Therapeutics' history and understand the potential risks before investing.
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio |